Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen

Welkom bij THIM Hogeschool voor Fysiotherapie & Bohn Stafleu van Loghum

THIM Hogeschool voor Fysiotherapie heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen. Je kunt je links eenvoudig registreren. Met deze gegevens kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL. Heb je een vraag, neem dan contact op met helpdesk@thim.nl.

» Andere revante producten voor THIM studenten en medewerkers.

Registreer

Om ook buiten de locaties van THIM, thuis bijvoorbeeld, van Mijn BSL gebruik te kunnen maken, moet je jezelf eenmalig registreren. Dit kan alleen vanaf een computer op een van de locaties van THIM.

Eenmaal geregistreerd kun je thuis of waar ook ter wereld onbeperkt toegang krijgen tot Mijn BSL.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Inloggen
Top
Quality of Life Research
Gepubliceerd in:

01-04-2015

Comparison of EQ-5D and SF-6D utilities in Pompe disease

Auteurs: T. A. Kanters, W. K. Redekop, M. E. Kruijshaar, A. T. van der Ploeg, M. P. M. H. Rutten-van Mölken, L. Hakkaart

Gepubliceerd in: Quality of Life Research | Uitgave 4/2015

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

Comparative studies between Euroqol-5D (EQ-5D) and ShortForm 6D (SF-6D) utilities have been performed for a number of diseases, but not yet for orphan diseases. Pompe disease is an orphan disease with a prevalence of <5/10,000, characterized by impaired ambulatory and pulmonary functioning. We compared the psychometric properties of EQ-5D and SF-6D in patients with this disease and assessed their convergent validity, discriminative ability and sensitivity to change.

Methods

EQ-5D utilities and SF-6D utilities were computed using the UK value set. Dimensions and utilities of the two instruments were compared by correlation coefficients and descriptive statistics. We assessed whether EQ-5D and SF-6D were able to discriminate between different levels of severity and examined sensitivity to change for patients with multiple observations.

Results

Correlations between theoretically related dimensions of the EQ-5D and SF-6D were highly significant and were moderate to strong (range rho = 0.409–0.564). Utility values derived from the two instruments were similar (mean EQ-5D = 0.670; mean SF-6D = 0.699) and correlated strongly (rho = 0.591). Discriminative properties were somewhat better for EQ-5D; mean changes and effect sizes were better for SF-6D.

Conclusions

Overall, we conclude that both instruments appear to be equally appropriate with respect to assessing utilities in Pompe disease, but neither of them performed excellently. The descriptive system of the SF-6D describes health states for Pompe disease more accurately. EQ-5D showed better discriminative properties. The SF-6D performed better with respect to sensitivity to change.
vorige artikel Measuring changes in health over time using the EQ-5D 3L and 5L: a head-to-head comparison of measurement properties and sensitivity to change in a German inpatient rehabilitation sample
volgende artikel Validity of EQ-5D-5L in stroke
Literatuur
1.
European Commission. (2000). Regulation (EC) no 141/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities, L18/1.
2.
Haffner, M. E. (2006). Adopting orphan drugs—two dozen years of treating rare diseases. New England Journal of Medicine, 354, 445–447.CrossRefPubMed
3.
Schey, C., Milanova, T., & Hutchings, A. (2011). Estimating the budget impact of orphan medicines in Europe: 2010–2020. Orphanet Journal of Rare Diseases, 6, 62.CrossRefPubMedCentralPubMed
4.
Drummond, M. F., Wilson, D. A., Kanavos, P., Ubel, P., & Rovira, J. (2007). Assessing the economic challenges posed by orphan drugs. International Journal of Technology Assessment in Health Care, 23, 36–42.CrossRefPubMed
5.
van der Ploeg, A. T., & Reuser, A. J. J. (2008). Pompe’s disease. The Lancet, 372, 1342–1353.CrossRef
6.
Ausems, M. G. E. M., Verbiest, J., Hermans, M. M. P., Kroos, M. A., Beemer, F. A., Wokke, J. H. J., et al. (1999). Frequency of glycogen storage disease type II in the Netherlands: Implications for diagnosis and genetic counselling. European Journal of Human Genetics, 7, 713–716.CrossRefPubMed
7.
Van der Beek, N. A. M. E., Van Capelle, C. I., Van der Velden-Van Etten, K. I., Hop, W. C. J., Van den Berg, B., Reuser, A. J. J., et al. (2011). Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease. Molecular Genetics and Metabolism, 104, 129–136.CrossRefPubMed
8.
Müller-Felber, W., Horvath, R., Gempel, K., Podskarbi, T., Shin, Y., Pongratz, D., et al. (2007). Late onset Pompe disease: Clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscular Disorders, 17, 698–706.CrossRefPubMed
9.
Van der Beek, N. A. M. E., De Vries, J. M., Hagemans, M. L., Hop, W. C., Kroos, M. A., Wokke, J. H., et al. (2012). Clinical features and predictors for disease natural progression in adults with Pompe disease: A nationwide prospective observational study. Orphanet Journal of Rare Diseases, 7, 88.CrossRefPubMedCentralPubMed
10.
Van der Beek, N. A. M. E., Hagemans, M. L. C., Reuser, A. J. J., Hop, W. C. J., van der Ploeg, A. T., Van Doorn, P. A., et al. (2009). Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscular Disorders, 19, 113–117.CrossRefPubMed
11.
Hagemans, M. L. C., Janssens, A., Winkel, L. P. F., Sieradzan, K. A., Reuser, A. J. J., Van Doorn, P. A., et al. (2004). Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology, 63, 1688–1692.CrossRefPubMed
12.
Kanters, T. A., Hagemans, M. L. C., Van der Beek, N. A. M. E., Rutten, F. F. H., van der Ploeg, A. T., & Hakkaart, L. (2011). Burden of illness of Pompe disease in patients only receiving supportive care. Journal of Inherited Metabolic Disease, 34, 1045–1052.CrossRefPubMedCentralPubMed
13.
Güngör, D., De Vries, J. M., Hop, W. C. J., Reuser, A. J. J., Van Doorn, P. A., van der Ploeg, A. T., et al. (2011). Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet Journal of Rare Diseases, 6, 34.CrossRefPubMedCentralPubMed
14.
Lamers, L. M., Bouwmans, C. A. M., Van Straten, A., Donker, M. C. H., & Hakkaart, L. (2006). Comparison of EQ-5D and SF-6D utilities in mental health patients. Health Economics, 15, 1229–1236.CrossRefPubMed
15.
Joore, M., Brunenberg, D., Nelemans, P., Wouters, E., Kuijpers, P., Honig, A., et al. (2010). The impact of differences in EQ-5D and SF-6D utility scores on the acceptability of cost-utility ratios: Results across five trial-based cost-utility studies. Value in Health, 13, 222–229.CrossRefPubMed
16.
Sach, T. H., Barton, G. R., Jenkinson, C., Doherty, M., Avery, A. J., & Muir, K. R. (2009). Comparing cost-utility estimates: Does the choice of EQ-5D or SF-6D matter? Medical Care, 47, 889–894.CrossRefPubMed
17.
18.
Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics, 21, 271–292.CrossRefPubMed
19.
20.
Brazier, J., Tsuchiya, A., Roberts, J., & Busschbach, J. (2004). A comparison of the EQ-5D and the SF-6D across seven patient groups. Health Economics, 13, 873–884.CrossRefPubMed
21.
Stavem, K., Frøland, S. S., & Hellum, K. B. (2005). Comparison of preference-based utilities of the 15D, EQ-5D and SF-6D in patients with HIV/AIDS. Quality of Life Research, 14, 971–980.CrossRefPubMed
22.
Szende, A., Leidy, N. K., Ståhl, E., & Svensson, K. (2009). Estimating health utilities in patients with asthma and COPD: Evidence on the performance of EQ-5D and SF-6D. Quality of Life Research, 18, 267–272.CrossRefPubMed
23.
Marra, C. A., Woolcott, J. C., Kopec, J. A., Shojania, K., Offer, R., Brazier, J. E., et al. (2005). A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Social Science and Medicine, 60, 1571–1582.CrossRefPubMed
24.
Fisk, J. D., Brown, M. G., Sketris, I. S., Metz, L. M., Murray, T. J., & Stadnyk, K. J. (2005). A comparison of health utility measures for the evaluation of multiple sclerosis treatments. Journal of Neurology, Neurosurgery and Psychiatry, 76, 58–63.CrossRefPubMedCentralPubMed
25.
Quanjer, P. H., Tammeling, G. J., Cotes, J. E., Pedersen, O. F., Peslin, R., & Yernault, J. C. (1993). Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. official statement of the European respiratory society. European Respiratory Journal. Supplement, 16, 5–40.CrossRef
26.
Medical Research Council. (1986). Aids to the examination of the peripheral nervous system. London: Tindall.
27.
De Vries, J. M., Van der Beek, N. A. M. E., Hop, W. C. J., Karstens, F. P. J., Wokke, J. H., De Visser, M., et al. (2012). Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: An open-label single-center study. Orphanet Journal of Rare Diseases, 7, 73.CrossRefPubMedCentralPubMed
28.
Field, A. P. (2009). Discovering statistics using SPSS. London: SAGE publications Ltd.
29.
Streiner, D. L., & Norman, G. R. (2008). Health measurement scales. Oxford: Oxford University Press.CrossRef
30.
Ghislandi, S., Apolone, G., Garattini, L., & Ghislandi, I. (2002). Is EQ-5D a valid measure of HRQoL in patients with movement disorders? The European Journal of Health Economics, 3, 125–130.CrossRefPubMed
31.
Janssen, M. F., Birnie, E., Haagsma, J. A., & Bonsel, G. J. (2008). Comparing the standard EQ-5D three-level system with a five-level version. Value in Health, 11, 275–284.CrossRefPubMed
32.
McTaggart-Cowan, H. M., Marra, C. A., Yang, Y., Brazier, J. E., Kopec, J. A., FitzGerald, J. M., et al. (2008). The validity of generic and condition-specific preference-based instruments: The ability to discriminate asthma control status. Quality of Life Research, 17, 453–462.CrossRefPubMed
33.
Khanna, D., Furst, D. E., Wong, W. K., Tsevat, J., Clements, P. J., Park, G. S., et al. (2007). Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. Quality of Life Research, 16, 1083–1092.CrossRefPubMed
34.
Lamers, L. M., McDonnell, J., Stalmeier, P. F. M., Krabbe, P. F. M., & Busschbach, J. J. V. (2006). The Dutch tariff: Results and arguments for an effective design for national EQ-5D valuation studies. Health Economics, 15, 1121–1132.CrossRefPubMed
Metagegevens
Titel
Comparison of EQ-5D and SF-6D utilities in Pompe disease
Auteurs
T. A. Kanters
W. K. Redekop
M. E. Kruijshaar
A. T. van der Ploeg
M. P. M. H. Rutten-van Mölken
L. Hakkaart
Publicatiedatum
01-04-2015
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 4/2015
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-014-0833-2

Andere artikelen Uitgave 4/2015

Factor analyses of a social support scale using two methods

Validation of clinical symptom IRT scores for diagnosis and severity assessment of common mental disorders

Living with orofacial conditions: psychological distress and quality of life in adults affected with Treacher Collins syndrome, cherubism, or oligodontia/ectodermal dysplasia—a comparative study

  • Open Access

Construct validity of SF-6D health state utility values in an employed population

Multiple imputation to deal with missing EQ-5D-3L data: Should we impute individual domains or the actual index?

The importance of productive patient–professional interaction for the well-being of chronically ill patients

  • Open Access